Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2018

01-11-2018 | ASO Author Reflections

ASO Author Reflections: Hypoxia-Induced PLOD2 Is a Key Regulator in Epithelial–Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer

Authors: Yuichiro Okumura, MD, Hidetoshi Eguchi, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2018

Login to get access

Excerpt

Currently, few effective treatment methods exist for patients with advanced or recurrent biliary tract cancer (BTC), mainly because most tumors are resistant to conventional chemotherapy and newer treatments.1 Elucidation of the molecular mechanism of chemoresistance is likely to lead to novel therapeutic strategies for BTC. Hypoxia is an environmental stimulus that plays a pivotal role in the development and progression of several cancers. Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) is a potential target gene that can be induced via the hypoxia-inducible factor-1α (HIF-1α) pathway under hypoxia conditions.2 This study focused on the roles of PLOD2 in BTC and investigated whether PLOD2 expression is associated with chemoresistance in BTC. …
Literature
1.
Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391–8.CrossRefPubMed
2.
Noda T, Yamamoto H, Takemasa I, et al. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver Int. 2012;32:110–8.CrossRefPubMed
3.
4.
Fischer KR, Durrans A, Lee S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015; 527:472–6.CrossRefPubMedPubMedCentral
Metadata
Title
ASO Author Reflections: Hypoxia-Induced PLOD2 Is a Key Regulator in Epithelial–Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer
Authors
Yuichiro Okumura, MD
Hidetoshi Eguchi, MD, PhD
Publication date
01-11-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 12/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6722-0

Other articles of this Issue 12/2018

Annals of Surgical Oncology 12/2018 Go to the issue

Colorectal Cancer

Controversies in Surgical Oncology: Does the Minimally Invasive Approach for Rectal Cancer Provide Equivalent Oncologic Outcomes Compared with the Open Approach?

Gynecologic Oncology

Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma

Health Services Research and Global Oncology

Alternative Ways to Study Global Variation in Cancer-Related Research Activity

ASO Author Reflections

ASO Author Reflections: BRCA Mutation Status for Personalizing Management of Recurrent Ovarian Cancer—A Multicenter Study

Breast Oncology

Patient-Reported Outcome Measures May Add Value in Breast Cancer Surgery

ASO Author Reflections

ASO Author Reflections: Tumor Cell Content and RNA Integrity of Surgical Tissues from Different Types of Tumors and Its Correlation with Ex Vivo and In Vivo Ischemia